Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody

2005 ◽  
Vol 19 (4) ◽  
pp. 261-266 ◽  
Author(s):  
Kanji Sugimoto ◽  
Norihiro Nishimoto ◽  
Tadamitsu Kishimoto ◽  
Kazuyuki Yoshizaki ◽  
Tsunehiko Nishimura
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Arthritis Model ◽  
Receptor Antibody ◽  
Interleukin 6 Receptor

scholarly journals Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

2019 ◽  
Vol 20 (18) ◽  
pp. 4633 ◽  
Author(s):  
Elinoar Hoffman ◽  
Michal A. Rahat ◽  
Joy Feld ◽  
Muna Elias ◽  
Itzhak Rosner ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Lipid Profile ◽  
Interleukin 6 ◽  
Density Lipoprotein ◽  
High Sensitivity ◽  
Mechanistic Explanation ◽  
Receptor Antibody ◽  
Increased Risk ◽  
Interleukin 6 Receptor

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon.

Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis

2006 ◽  
Vol 20 (3) ◽  
pp. 67-68
Author(s):  
Rainer H. Straub ◽  
Peter Harle ◽  
Seizo Yamana ◽  
Takemasa Matsuda ◽  
Kiyoshi Takasugi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Antibody Therapy ◽  
Adrenal Androgen ◽  
Receptor Antibody ◽  
Interleukin 6 Receptor ◽  
Androgen Secretion

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

2009 ◽  
Vol 31 (4) ◽  
pp. 451-456 ◽  
Author(s):  
Shin-ya Kawashiri ◽  
Atsushi Kawakami ◽  
Satoshi Yamasaki ◽  
Takahiro Imazato ◽  
Naoki Iwamoto ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Serum Lipid ◽  
Lipid Levels ◽  
Receptor Antibody ◽  
Serum Lipid Levels ◽  
Interleukin 6 Receptor
Sign in / Sign up

Export Citation Format

Share Document